Evidence map›Paper›PMID 31167787›Full record

ArticleThe Journal of biological chemistry2019

Protein painting, an optimized MS-based technique, reveals functionally relevant interfaces of the PD-1/PD-L1 complex and the YAP2/ZO-1 complex.

Amanda Haymond, Douglass Dey, Rachel Carter, Angela Dailing, Vaishnavi Nara, Pranavi Nara, Sravani Venkatayogi, Mikell Paige, Lance Liotta, Alessandra Luchini

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. State-of-the-Art and Future Directions in Structural Proteomics.Molecular & cellular proteomics : MCP · 2025
    Review
  2. Article
  3. Laser capture microdissection.Nature reviews. Methods primers · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Amanda HaymondCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110 ahaymond@gmu.edu.ORCID 0000-0002-9553-275X
Douglass DeyCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110.
Rachel CarterCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110.
Angela DailingCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110.
Vaishnavi NaraThomas Jefferson High School for Science and Technology, Alexandria, Virginia 22312.
Pranavi NaraUniversity of Pittsburgh, Pittsburgh, Pennsylvania 15260.
Sravani VenkatayogiCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110.
Mikell PaigeDepartment of Chemistry and Biochemistry, George Mason University, Fairfax, Virginia 20110.ORCID 0000-0001-9292-1277
Lance LiottaCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110.
Alessandra LuchiniCenter for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia 20110.
George Mason University · USThomas Jefferson School of Law · USUniversity of Pittsburgh · US

Funding

Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
Probes to target the 3-way hotspot of IL1RacP to abolish aberrant interleukin inflammationR01AR068436 · NIAMS · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2015 to 2017
$1.7M
Protein painting identifies therapeutic targets at protein-protein interfacesR33CA206937 · NCI · GEORGE MASON UNIVERSITY · PI LIOTTA, LANCE ALLEN · 2016 to 2018
$1.2M
EPA EP-C-18-007NCI NIH HHS R33 CA206937NIAMS NIH HHS R01 AR068436NIGMS NIH HHS P41 GM103311
6 · The paper itself

Abstract

Protein-protein interactions lie at the heart of many biological processes and therefore represent promising drug targets. Despite this opportunity, identification of protein-protein interfaces remains challenging. We have previously developed a method that relies on coating protein surfaces with small-molecule dyes to discriminate between solvent-accessible protein surfaces and hidden interface regions. Dye-bound, solvent-accessible protein regions resist trypsin digestion, whereas hidden interface regions are revealed by denaturation and sequenced by MS. The small-molecule dyes bind promiscuously and with high affinity, but their binding mechanism is unknown. Here, we report on the optimization of a novel dye probe used in protein painting, Fast Blue B + naphthionic acid, and show that its affinity for proteins strongly depends on hydrophobic moieties that we call here "hydrophobic clamps." We demonstrate the utility of this probe by sequencing the protein-protein interaction regions between the Hippo pathway protein Yes-associated protein 2 (YAP2) and tight junction protein 1 (TJP1 or ZO-1), uncovering interactions via the known binding domain as well as ZO-1's MAGUK domain and YAP's N-terminal proline-rich domain. Additionally, we demonstrate how residues predicted by protein painting are present exclusively in the complex interface and how these residues may guide the development of peptide inhibitors using a case study of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1). Inhibitors designed around the PD-1/PD-L1 interface regions identified via protein painting effectively disrupted complex formation, with the most potent inhibitor having an IC

Indexed as

Adaptor Proteins, Signal TransducingAmino AcidsAzo CompoundsB7-H1 AntigenBinding SitesHumansHydrophobic and Hydrophilic InteractionsMass SpectrometryProgrammed Cell Death 1 ReceptorProtein BindingTranscription FactorsYAP-Signaling ProteinsZonula Occludens-1 ProteinAdaptor Proteins, Signal TransducingAmino AcidsAzo CompoundsB7-H1 AntigenCD274 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorTJP1 protein, humanTranscription FactorsYAP1 protein, humanYAP-Signaling ProteinsZonula Occludens-1 Proteincell signalingimmune checkpoint inhibitormass spectrometry (MS)PD-L1programmed cell death protein 1 (PD-1)protein paintingprotein-protein interactionstructural biologyYes-associated protein (YAP)ZO-1

Identifiers

PMID31167787
PMCPMC6643031
OpenAlexW2963466951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.